Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Objective: This study is to observe the safety and therapeutic effect of cryoablation
combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary
lung cancer (MPLC) patients.
Methods: In this study, 20 patients with MPLC who conform to the admission criteria are
enrolled and began to receive treatment with Camrelizumab combined with Apatinib after
cryoablation.